Higher bioavailability of magnesium citrate as compared to magnesium oxide shown by evaluation of urinary excretion and serum levels after single-dose administration in a randomized cross-over study

Table 3 Analysis of serum magnesium concentration (in mmol/L)

Time point	Study product	Mean (SD)	Log-ANOVA
			Adj. mean ratio	95% CI	p-value
Predose	Biolectra	0.87 (0.042)	1.00	(0.98, 1.01)	0.5169
Predose	Verla	0.87 (0.042)	1.00	(0.98, 1.01)	0.5169
60 min	Biolectra	0.88 (0.043)	1.01	(1.00, 1.02)	0.1991
60 min	Verla	0.88 (0.041)	1.01	(1.00, 1.02)	0.1991
2 h	Biolectra	0.89 (0.040)	1.03	(1.01, 1.04)	0.0008*
2 h	Verla	0.92 (0.037)	1.03	(1.01, 1.04)	0.0008*
3 h	Biolectra	0.85 (0.041)	1.03	(1.02, 1.04)	<.0001*
3 h	Verla	0.88 (0.040)	1.03	(1.02, 1.04)	<.0001*
4 h	Biolectra	0.88 (0.045)	1.03	(1.01, 1.04)	0.0016*
4 h	Verla	0.90 (0.040)	1.03	(1.01, 1.04)	0.0016*
5 h	Biolectra	0.87 (0.044)	1.03	(1.01, 1.04)	0.0036*
5 h	Verla	0.89 (0.043)	1.03	(1.01, 1.04)	0.0036*
6 h	Biolectra	0.86 (0.044)	1.02	(1.01, 1.04)	0.0026*
6 h	Verla	0.88 (0.039)	1.02	(1.01, 1.04)	0.0026*
9 h	Biolectra	0.89 (0.038)	1.02	(1.00, 1.03)	0.0979
9 h	Verla	0.90 (0.048)	1.02	(1.00, 1.03)	0.0979
24 h	Biolectra	0.88 (0.049)	1.00	(0.99, 1.01)	0.8756
24 h	Verla	0.88 (0.043)	1.00	(0.99, 1.01)	0.8756

CI confidence interval, Mg magnesium, SD standard deviation; Biolectra = Biolectra® Magnesium 300 mg Kapseln; Verla = Magnesium Verla® purKaps. Adjusted mean ratio, 95% CI and p-value are based on an ANOVA model with study product, sequence, period and subject within sequence as considered effects. Statistical significance at a level of 5% is given if the 95% confidence interval of the adjusted mean ratio does not include 1, respectively if the p-value is <0.05. Statistical significance is denoted by an asterisk (*)

ISSN: 2055-0928